Erasca (ERAS) Income towards Parent Company (2020 - 2026)
Erasca's (ERAS) quarterly Income towards Parent Company came in at -$860.7 million in Q1 2026, down 2218.06% YoY from $40.6 million in Q1 2025, and down 2423.74% on a QoQ basis from -$34.1 million in Q4 2025.
Analysis
Erasca (ERAS) Income towards Parent Company (2020 - 2026) Analysis & Trends
Erasca (ERAS) has 7 years of Income towards Parent Company data on file, last reported at -$860.7 million in Q1 2026.
- Quarterly Income towards Parent Company fell 2218.06% year-over-year to -$860.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.0 billion (down 267.67% YoY) and the FY2025 annual result came in at -$383.1 million, down 98.94% from the prior year.
- Income towards Parent Company retreated to -$860.7 million in Q1 2026, from -$34.1 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of -$29.4 million in Q4 2023 to a low of -$860.7 million in Q1 2026.
- A 5-year average of -$118.3 million and a median of -$55.7 million in 2025 frame the typical range for Income towards Parent Company.
- Annual changes were most pronounced in 2023 — Income towards Parent Company surged 78.8% — and 2026, when it slumped 2218.06%.
- Tracing ERAS's Income towards Parent Company over 5 years: stood at -$138.7 million in 2022, then surged by 78.8% to -$29.4 million in 2023, then dropped by 27.25% to -$37.4 million in 2024, then advanced by 8.84% to -$34.1 million in 2025, then tumbled by 2423.74% to -$860.7 million in 2026.
- The last three Income towards Parent Company figures came in at -$860.7 million (Q1 2026), -$34.1 million (Q4 2025), and -$51.1 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn |
| 10 | Erasca | 5.02 Bn | 5.02 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -44.08 Mn |
| Mar 31, 2026 | -183.46 Mn |
| Dec 31, 2025 | -29.04 Mn |
| Sep 30, 2025 | -30.58 Mn |
| Jun 30, 2025 | -33.88 Mn |
| Mar 31, 2025 | -30.97 Mn |
| Dec 31, 2024 | -30.43 Mn |
| Sep 30, 2024 | -31.37 Mn |
| Jun 30, 2024 | -63.20 Mn |
| Mar 31, 2024 | -35.02 Mn |
| Dec 31, 2023 | -29.70 Mn |
| Sep 30, 2023 | -30.36 Mn |
| Jun 30, 2023 | -31.78 Mn |
| Mar 31, 2023 | -33.20 Mn |
| Dec 31, 2022 | -135.25 Mn |
| Sep 30, 2022 | -35.49 Mn |
| Jun 30, 2022 | -35.61 Mn |
| Mar 31, 2022 | -36.46 Mn |
| Dec 31, 2021 | -30.97 Mn |
| Sep 30, 2021 | -46.07 Mn |